Ahmet KİPER, M. Abdurrahim İMAMOĞLU, Adnan GÜCÜK, Can TUYGUN

Benign prostat hiperplazisi'nin semptomatik tedavisinde terazosinin etkinliği ve güvenilirliği (Çift kör plesebo kontrollü çalışma)

Amaç: Bu çalışmada, benign prostat hiperplazisi nedeniyle gelişen üriner semptomaları tedavi etmek için bir alfa antagonist olan terazosinin etkinliğini ve yan etkilerini plasebo ile karşılaştırmayı amaçladık. Materyal ve Metod: Benign prostat hiperplazisine bağlı infravezikal obstrüktif şikayetleri olan 60 hastanın 30'una plesebo diğer 30'una selektif-alfa-l adrenerjik reseptör blokörü olan terazosin verilerek çift kör paralel bir çalışma yapıldı ve sonuçları değerlendirildi. Bulgular: Terazosin verilen hastalarda maksimum ve orta-lama idrar akım hızı istatistiksel olarak anlamlı bir artış gösterdi (P

The effectiviness and safety of terazosine for the symptomatic treatment of benign prostatic hyperplasia (Double blind controlled study)

Aim: in this study, we aimed to compare effectiveness and side effects of terazosine versus placebo for treatment of urinary symproms due to BPH. Materials and Methods: 60 patients with infravesical obstructive complaints due to benign prostatic hyperplasia participated in this double-blind parallel study. 30 patients were randomized to placebo group and 30 patients to terazosine group, which is an alpha-1 adrenergic receptor blocker, and the results of both groups vvere compared. Results: in the terazosine group, maximal and mean urinary flow rates increased significantly (p

PDF

___

1. Abrams P. objective Evaluation of Bladder Outler Obstruction. Br J.Urol 1995; 76:11.
2. Berry SJ, Coffey OS, Walsh PC, et al. The Development Of Human Benign Prostatic Hyperplasia With Age. J Urol 1984; 132:474.
3. Isaacs JT, Coffey DS. Etiology and Disease Process of Benign Prostatic Hyperplasia. Prostate 1989; 2:33. 4. Mudiyala R, Ahmed A. Effect of Terazosin on Clinical Benign Prostatic Hyperplasia in older adults. Division of Gerontology and Geriatric . Medicine, School of Medicine , University of Alabama of Birmingham, USA. J Am Geriatr. Soc.2003; 51:424-6.
5. Mebust WK, Holtgrewe HL, Cockett ATK, et al. Transurethral prostatectomy: immediate and post- operati ve complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989; 141:243.
6. De Campos Feire G. BPH: The basis of pharmaco- logical treatment. Non-Surgical Treatment of BPH (Fizpatrick JM, ed) London, Churchill Livingstone. 47,1992.
7. Beduschi MC, Beduschi R, Oesterling JE. Alpha- blochade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha-1a adrenergic antagonist. Urology 1998; 51:861-72.
8. Tanaka Y, Masumari N, Itoh N, Sato Y, Takahashi A, Ogura H, Furuya S, Tsukamoto T. Urodynamic effects of Terazosin treatment for japanase patients with symptomatic benign prostatic hyperplasia Department of Urology, Sapporo Medical University School of Medicjne, Sapporo Japan. J Urol.2002; 167:2492-5.
9. Kobayashi S, Tang R, Shapiro E, et al. Characterisation and localization of prostaic alphal adrenoceptors using radiologiand receptor binding on slide mounted tissue section. J Urol 1993; 150: 2002.
10. Speakman Mj, Brading AF, Gilpin CJ, et al. Bladder outflow obstruction: a cause of denervation super- sensitivity. J Urol 1987; 138:1461.
11. Boreham PF, Braithwaite P, Milewski P, Pearson H. Alpha-adrenergic blockers in prostatism. Br J Surg. 1977; 64:756.
12.Gerstenberg T, Blaabjerg J, Nielsen ML, Clausen S. Phenoxybenzamine reduces bladder outlet obstruction in benign prostatic hyperplasia. A urodynamic investigation. Invest Urol 1980; 18:29.
13. Furuya S, Kumamota Y, Yokoyama E, et al. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 1982; 128:836.
14. Chappie CR, Aubry ML, James S, et al. Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localiza- tion. BrJ Urol 1989; 63: 487.
15. Breslin D, Fields DW, Chou TC, et al. Medical man¬ agement of benign prostatic hyperplasia: A canine model comparing the in vivo efficacy of alphal adrenergic antagonists in the prostate. J Urol 1993; 149:395.
16. Hedlund H, Anderson KE. Efects of prazosin in patients with benign prostatic obstruction. J Urol 1983; 130: 275-278.
17.Martorana G, Gilberti C, Damonte P, Ciprandi G, Dirienzo W, Giuliani L. The effects of prazosin in benign prostatic hypertrophy a placebo-controlled double-blind study. IRCS Med Sci 1984; 12:11-12.
18. Kirby RS, Coppinger SWC, Corcoran MO, Chappie CR, Flannigan M, Milroy EJG. Prazosin in the treat¬ment of prostatic obstruction.: A placebo-controlled study. BrJ Urol 1987; 60: 136-143.
19.Lepor H, Auerbach S, Puras-Baez A, et al. A ran¬domized, placebo controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467.
20. DiSilverio F. Use of terazosin in the medical treat- ment of benign prostatic hyperplasia: experiences in Italy. Br J Urol 1992; 70(Suppl 1): 22.
21. Lloyd SN, Buckley JF, Chilton CP, et al. Terazosin in the treatment of benign prostatic hyperplasia: a mul- ticentre, placebo-controlled trial. BrJ Urol 1992; 70 (Suppl 1): 17.
22. Lepor H. Long-term safety and effectiveness of tera- zosin for the treatment of BPH. Urology 1995; 45:406.
23. Lepor H, Williford WO. The efficacy of terazosin finansteride, or both in benign prostatic hiperpluzia. J Of Medicine 1996; 365: 533.
24. Lowe FC, Olson PJ, Padley RJ. Effects of Terazosin therapy on blood pressure in man with benign pro- static hyperplasia concurrently treated, with other antihypertensive medications. Urology 1999; Jul 54:81-5.
25. Lepor H, Jones K, Willifard W . The mechanism adverse events associated with terazosin. J Urol 2000; 163:1134-7.